Jovens com SOP e DM2: Estudo de Casos Sobre Atendimento Público em Saúde

Giovana von Dokonal Ferreira; Ana Paula von Dokonal Ferreira; Cristina Marschall; Gabriela Santos Bianchin; Laura Daroit; Karol Arias Fernandes; Emily Nefertiti Balbinot; Luciano Henrique Pinto

doi:10.36489/saudecoletiva.2024v14i92p13976-13991

Autores

Giovana von Dokonal Ferreira https://orcid.org/0000-0002-9380-5224
Ana Paula von Dokonal Ferreira https://orcid.org/0009-0002-3041-0679
Cristina Marschall https://orcid.org/0000-0001-5254-4809
Gabriela Santos Bianchin https://orcid.org/0000-0001-8547-6937
Laura Daroit https://orcid.org/0000-0002-1757-4065
Karol Arias Fernandes Universidade da Região de Joinville https://orcid.org/0000-0003-2316-8271
Emily Nefertiti Balbinot https://orcid.org/0000-0001-9496-8706
Luciano Henrique Pinto https://orcid.org/0000-0003-0250-7502

DOI:

https://doi.org/10.36489/saudecoletiva.2024v14i92p13976-13991

Palavras-chave:

Síndrome do ovário policístico, Diabetes Mellitus tipo 2, Obesidade, Metformina

Resumo

Objetivo: Descrever a relação da síndrome do ovário policístico (SOP) com a diabetes mellitus tipo 2 (DM2), seus fatores de risco, bem como opções terapêuticas e as consequências desse distúrbio sobre a saúde da mulher. Método: Foi realizada a análise de quatro prontuários de pacientes portadoras da SOP no município de Joinville. Resultado: Entre 469 mulheres com SOP e DM2, 4 atendiam os critérios. Observa-se que a metformina pode ser menos eficaz para o hirsutismo em certos subgrupos, enquanto estudos indicam que o tratamento com metformina e ACH melhora parâmetros bioquímicos, mas não obesidade. Isto implica que a escolha do tratamento deve ser baseada nos sintomas, observando benefícios bioquímicos do tratamento combinado; visando os principais distúrbios endócrinos: hiperinsulinemia e hiperandrogenismo. Conclusão: Observou-se a correlação entre SOP e obesidade no desenvolvimento de diabetes e a necessidade de se estabelecer um tratamento para benefício tanto do sistema reprodutor quanto para o cardiovascular.

Referências

Azziz R. Polycystic Ovary Syndrome. Obstetrics & Gynecology. 2018 Aug;132(2):321–36. Available from: https://journals.lww.com/greenjournal/abstract/2018/08000/polycystic_ovary_syndrome.9.aspx.

Yin RK. Case study research and applications: design and methods. SAGE Publications, 2017.

STAKE, Robert E. Qualitative research: studying how things work. Guilford Press, 2010.

Fraison E, Kostova E, Moran LJ, Bilal S, Ee CC, Venetis C, et al. Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2020 Aug 13;(8). Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005552.pub3/full.

Melin J, Forslund M, Alesi S, Terhi P, Romualdi D, Spritzer PM, et al. Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis. The Journal of Clinical Endocri- nology and Metabolism. 2023 Aug 9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10795934/.

Teede HJ, Chau TT, Joop JEL, Anuja D, Moran LJ, Terhi TP, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. European journal of endocrinology. 2023 Aug 1;189(2):G43–64. Available from: https://academic.oup.com/ejendo/article/189/2/G43/7242362.

Wu L, Liu Y, Huang X, Lin K, Liu Y, Li Z, et al. Oral contraceptives (OCs) in combination with metformin versus OCs alone on metabolism in nonobese polycystic ovary syndrome: A meta‐analysis and systematic review of randomized controlled trials. Clinical Endocrinology. 2023 Apr 7;99(1):3–16. Available from: https://onlinelibrary.wiley.com/doi/10.1111/cen.14895.

Nelson AL, Cwiak CA. Combined oral contraceptives (COCs). In: Hatcher RA (Eds.). Contraceptive Technology. 20th ed. Ardent Media, 2011. p. 249–341.

Speroff L, Fritz MA. clinical gynecologic endocrinology and infertility. 9th ed. Philadelphia: Wolters Kluwer Health, 2020.

Forslund M, Melin J, Alesi S, Piltonen T, Romualdi D, Tay CT, et al. Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis. European Journal of Endocrinology [Internet]. 2023 Jul 20;189(1):S1–16. Available from: https://pubmed.ncbi.nlm.nih.gov/37440702/.

, Goldberg A, Graca S, Liu J, Rao V, Selma Feldman Witchel, Pena A, et al. Anti‐obesity pharmacological agents for poly- cystic ovary syndrome: A systematic review and meta‐anal- ysis to inform the 2023 international evidence‐based guide-line. Obesity reviews. 2024 Feb 14. Available from: https://pubmed.ncbi.nlm.nih.gov/38355887/.

Prefeitura de Joinville. REMUME - Relação municipal de medicamentos essenciais. Secretaria de Joinville. Available from: https://www.joinville.sc.gov.br/public/portaladm/pdf/jornal/3c415e8ee2afb4dcd0a97676aefac34d.pdf.

Loh HH, Yee A, Loh HS, Kanagasundram S, Francis B, Lim LL. Sexual dysfunction in polycystic ovary syndrome: a systematic review and meta-analysis. Hormones. 2020 May 27;19(2);413–423. Available from: https://link.springer.com/article/10.1007/s42000-020-00210-0.

Hong X, Qin P, Yin J, Shi Y, Xuan Y, Chen Z, et al. Clinical manifestations of polycystic ovary syndrome and associations with the vaginal microbiome: a cross-sectional based exploratory study. Frontiers in Endocrinology. 2021 Apr 23;12. Available from: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.662725/full.